Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial

Status Recruiting

Clinical Trial Summary

Anticoagulant treatment for non-valvular atrial fibrillation (AF) associated with cerebral infarction/ TIA is one of the recognized treatment of stroke prevention. The ACC/AHA and national guidelines for the management of anticoagulation recommend that most of AF patients with cerebral infarction or TIA should be administrated anticoagulant therapy within 14 days of symptom onset, while European guidelines recommend that the timing of the initiation of non-vitamin K antagonist oral anticoagulants (NOACs) for AF patients with cerebral infarction or TIA is association with stroke severity in light of the "1-3-6-12" principle. However, there are still many problems about the use of NOACs in ischemic stroke with AF. for example, it is unclear what time to begin NOACs as to difference in stroke severity, ages, comorbidity with hypertension, diabetes, heart failure, liver and kidney dysfunction and bleeding risks. Thus, the timing of the initiation of NOACs is yet to be further studied. Current urgent need is to develop a guideline-based specific regimen in which the benefit-risk factors are further balanced with a combination of NHISS, CHA2DS2-VASC and HAS-BLED score. Rivaroxaban, a direct coagulation factor Ⅹa inhibitor, blocks the formation of the clot. ROCKET-AF study has shown that the efficacy of rivaroxaban is not inferior to that of warfarin in AF patients on stroke prevention, and rivaroxaban has a significantly decreased bleeding risk compared with warfarin. Recent study indicates that early administration with rivaroxaban for AF patients within 14 days of onset does not significantly increase hemorrhagic transformation. However, the relevant clinical data of the efficacy and safety of early initiation of rivaroxaban in AF patients with cerebral infarction or TIA are lacking in China. Therefore, the investigators conduct a multicenter cohort study to investigate the safety of early rivaroxaban in the AF patient with cerebral infarction or TIA within 12 days of onset.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03749057
Study type	Interventional
Source	General Hospital of Shenyang Military Region
Contact	Xinhong Wang, Doctor
Phone	15309885658
Email	450341972@qq.com
Status	Recruiting
Phase	Phase 4
Start date	November 20, 2018
Completion date	June 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02551003` - Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy	Phase 1/Phase 2
Completed	`NCT03281590` - Stroke and Cerebrovascular Diseases Registry
Recruiting	`NCT03605381` - MORbidity PRevalence Estimate In StrokE
Completed	`NCT00684515` - Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)	Phase 2
Not yet recruiting	`NCT04082091` - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Completed	`NCT01915368` - Determining Optimal Post-Stroke Exercise (DOSE)	N/A
Terminated	`NCT01684462` - The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke	Phase 2
Completed	`NCT00386191` - Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment	Phase 4
Completed	`NCT00004734` - Vitamin Therapy for Prevention of Stroke	Phase 3
Completed	`NCT02684825` - Detection of Silent Atrial Fibrillation aFter Ischemic StrOke	N/A
Completed	`NCT02248233` - Nimodipine for Treating Acute Massive Cerebral Infarction	Phase 4
Completed	`NCT02963545` - TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke	N/A
Completed	`NCT02511249` - Early Determinants of Multidimensional Outcome at School Age After Neonatal Arterial Ischemic Stroke	N/A
Completed	`NCT02101606` - Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke	Phase 2
Completed	`NCT01500421` - Safty and Feasibility Study of Therapeutic Cooling in Acute Ischemic Stroke (COOLAID Øresund)	Phase 2
Completed	`NCT00829361` - Stroke Telemedicine for Arizona Rural Residents Trial	N/A
Recruiting	`NCT01003470` - Treating Apoplectic Sequela With Acupuncture: a Randomized Controlled Study	Phase 2
Terminated	`NCT00331890` - ICTUS Study: International Citicoline Trial on Acute Stroke	Phase 3
Not yet recruiting	`NCT04696523` - Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage	Phase 2
Completed	`NCT03741400` - Virtual Reality Glove for Hand and Arm Rehabilitation After Stroke	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation — ERSAF

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms